Gecina, which owns 98.6% of Gecimed, announces that it intends to file a proposed buyout offer followed by a squeeze on the shares of Gecimed.
Gecina believes that there is no longer appropriate to retain its subsidiary Gecimed as listed structure.
Ricol Lasteyrie & Associates has been appointed as independent expert by the Board of Directors Gecimed, for the purpose of issuing a fairness opinion on the offer price to be determined by Gecina.
This project offers should be filed with the AMF on May 31 next.
In the meantime, the share price Gecimed is suspended.
The payment of a dividend of EUR 0.17 per share, which will be proposed at the Annual General Gecimed May 30 next, is not challenged by this operation.
Gecina believes that there is no longer appropriate to retain its subsidiary Gecimed as listed structure.
Ricol Lasteyrie & Associates has been appointed as independent expert by the Board of Directors Gecimed, for the purpose of issuing a fairness opinion on the offer price to be determined by Gecina.
This project offers should be filed with the AMF on May 31 next.
In the meantime, the share price Gecimed is suspended.
The payment of a dividend of EUR 0.17 per share, which will be proposed at the Annual General Gecimed May 30 next, is not challenged by this operation.
没有评论:
发表评论